Novartis lifts full-year earnings outlook

This post was originally published on this site

The Swiss drugmaker said in a statement that when excluding Sandoz, the generic-drug division that will be spun off during the second half of the year, group core operating income would grow by a “high single digit to low double digit” percentage.

It had previously forecast a “mid-to-high single digit” increase.